T.

R

PTO-1449 REPRODUCED AUG 1 6 2000			ATTORNEY DOCKET NO. 1440.1023-011	APPLICATION NO. 09/589,777			
	INFO	RMATION DISCLOSURE C. IN AN APPLICATION	CEMABY OFF	APPLICANT Vikas P. Sukhatme			
August 11, 2000 (Use several sheets if necessary)				FILING DATE June 8, 2000	GROUP Not assigned.		
			v.s.	PATENT DOCUMENTS			
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
				1		REC	EIVED
						SEP 3	0 2000
	+					TECH CENTE	R 4500/2000
	<u> </u>]	FORETG	N PATENT DOCUMENTS	<u></u>		
	l.	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION CEIVED
						O'	T 0.2 2000
						TECHO	ENTER 1600/2990
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
NW	AU	Hohenester, et al., "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1.5 Å Resolution", EMBO Journal:17(6):1656-1664 (1998)					
	AV	Nguyen, et al., "Genetic Strategies for Anti-Angiogenic Therapy of Solid Tumors", p.1 (1997).					
	AW	Boehm, et al., "Zinc-Binding of Endostatin is Essential for Its Antiangiogenic Activity", Biochemical and Biophysical Research Communication, 252:190-194 (1998).					
	AX	Ding et al., "Zinc-Dependent Dimers Observed in Crystals of Human Endostatin", Proc. Natl. Acad. Sci., 95:10443-10448 (1998).					
	AY	Folkman, J., "Endogenous Inhibitors of Angiogenesis", The Harvey Lectures, Series 92:65-82 (1998).					
	AZ	Dhanabal, et al., "Cloning, Expression, and In Vitro Activity of Human Endostatin", Biochemical and Biophysical Research Communications, 258:345-352 (1999).					
\bigvee	AR2	Bachelot, T. et al., "Retrovirus-medicated gene transfer of an Angiostatin-Endostatin fusion protein with enhanced anti-tumor / properties in vivo", Proceedings of the 89th Annual Meeting of the American Association for Cancer Research 39:271 (March 1998)					
Date considered 4-24-01							

OIPE